312 related articles for article (PubMed ID: 22481235)
41. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Enzinger PC; Burtness BA; Niedzwiecki D; Ye X; Douglas K; Ilson DH; Villaflor VM; Cohen SJ; Mayer RJ; Venook A; Benson AB; Goldberg RM
J Clin Oncol; 2016 Aug; 34(23):2736-42. PubMed ID: 27382098
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
[TBL] [Abstract][Full Text] [Related]
43. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V
J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
[TBL] [Abstract][Full Text] [Related]
45. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
46. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
47. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
48. Irinotecan, cisplatin, and radiation in esophageal cancer.
Ilson DH; Minsky B; Kelsen D
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
50. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
51. Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
Mirinezhad SK; Somi MH; Shirmohamadi M; Seyednejad F; Jangjoo AG; Ghojazadeh M; Mohammadzadeh M; Naseri AR; Nasiri B
Asian Pac J Cancer Prev; 2013; 14(6):3921-4. PubMed ID: 23886207
[TBL] [Abstract][Full Text] [Related]
52. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
[TBL] [Abstract][Full Text] [Related]
55. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
[TBL] [Abstract][Full Text] [Related]
56. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Pera M; Gallego R; Montagut C; Martín-Richard M; Iglesias M; Conill C; Reig A; Balagué C; Pétriz L; Momblan D; Bellmunt J; Maurel J
Ann Oncol; 2012 Mar; 23(3):664-670. PubMed ID: 21652581
[TBL] [Abstract][Full Text] [Related]
57. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Saeki H; Morita M; Tsuda Y; Hidaka G; Kasagi Y; Kawano H; Otsu H; Ando K; Kimura Y; Oki E; Kusumoto T; Maehara Y
Ann Surg Oncol; 2013 Dec; 20(13):4267-73. PubMed ID: 23943036
[TBL] [Abstract][Full Text] [Related]
58. Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
Mirinezhad SK; Somi MH; Seyednezhad F; Jangjoo AG; Ghojazadeh M; Mohammadzadeh M; Naseri AR; Nasiri B
Asian Pac J Cancer Prev; 2013; 14(3):1677-80. PubMed ID: 23679255
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
[TBL] [Abstract][Full Text] [Related]
60. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
Michel P; Adenis A; Di Fiore F; Boucher E; Galais MP; Dahan L; Mirabel X; Hamidou H; Raoul JL; Jacob JH; Hellot MF; Prod'homme S; Paillot B
Br J Cancer; 2006 Sep; 95(6):705-9. PubMed ID: 16967056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]